The AI in Respiratory Diseases Market Size is predicted to witness a 29.4% CAGR during the forecast period for 2023-2031.
AI is revolutionizing the field of respiratory diseases by aiding in early diagnosis, personalized treatment, and remote monitoring. It can analyze medical images, predict disease progression, and even assist in drug discovery. AI also helps patients manage conditions like asthma and COPD while monitoring air quality and providing real-time insights. These advancements hold promise for improving patient care and outcomes in respiratory health.
Clinical data, chest scans, lung pathology, and pulmonary function testing can all be used by AI to aid in the diagnosis and prognosis of pulmonary disorders. The advent of new digital tools drives market expansion, and fields like genomics, medical imaging, and electronic health records are contributing to an unprecedented explosion in the volume and complexity of healthcare-related data. Because of this explosive expansion, more and more clinically relevant applications based on AI have been developed.
Expert pulmonologists who have studied AI theory and practice will be in a strong position to exploit emerging career prospects in both clinical practice and academic research. This review aims to educate pulmonologists and other interested readers about artificial intelligence's potential applications in this field of medicine. The advancement of healthcare technology has led to an anticipated uptick in the use of AI in respiratory diseases.
However, several negative aspects seriously restrain the expansion of AI in the respiratory diseases market. Lack of knowledge and high cost are hindering the AI in respiratory diseases market growth. In addition, the COVID-19 pandemic has had a major effect on the market for providers of artificial intelligence in respiratory diseases medicine. Several factors have contributed to this effect. Genomics, diagnostics, drug development, and individualized treatment are just some of the areas where artificial intelligence technologies like deep learning and the processing of natural language have found use. During the recent COVID-19 epidemic, the value of AI in responding to medical emergencies and improving our understanding of complex diseases became clear.
Competitive Landscape
Some Major Key Players In The AI in Respiratory Diseases Market:
- ArtiQ
- Dectrocel Healthcare
- DeepMind Health
- GE Healthcare
- Icometrix
- Infervision
- Philips Healthcare
- PneumoWave
- Respiray
- Siemens Healthineers
- Swaasa AI
- THIRONA
- Verily
- VIDA Diagnostics Inc
- Zynnon
Market Segmentation:
The AI in respiratory diseases market is segmented based on the indication, imaging type, and end-use. As per the indication, the market is segmented into chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary infection. By imaging type, the market is segmented into MRI, CT Scan, and ePRO. According to end-use segment, the market is segmented into hospitals, diagnostic centres, ambulatory surgical centers, and others.
Based On The Imaging Type, The CT Scan AI In The Respiratory Diseases Segment Is Accounted As A Major Contributor To The AI In The Respiratory Diseases Market
The CT Scan AI in the respiratory diseases category is expected to hold a maximum global market share because it helps in the diagnosis of lung problems such as pneumonia, cancer, blood clots, and smoking-related damage.
The Diagnostic Centers Segment Witnessed Growth At A Rapid Rate
The diagnostic centers are expected to grow rapidly in the global AI in respiratory diseases market. The crucial role of diagnostic centers in the diagnosis of diseases at an early stage cannot be overstated. Early diagnosis is solution to the successful treatment of different diseases, including cancer, cardiovascular disease. Screening tests and preventative medical examinations are available at medical clinics that specialize in diagnosing and treating such conditions, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American AI In Respiratory Diseases Market Holds A Significant Revenue Share
The North American AI in respiratory diseases market activity is anticipated to record the largest market share in revenue in the near future. It can be attributed to the expansion of financial resources and time spent on R&D. As the need for innovative healthcare services grows, governments, institutions, and investors are pouring more money into projects that aim to apply artificial intelligence to the practice of respiratory disease medicine. The need for AI in Respiratory Diseases is anticipated to increase as a result of this region.
AI in Respiratory Diseases Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 29.4 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Indication, Imaging Type, End-Use |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Siemens Healthineers, VIDA Diagnostics Inc,THIRONA, Infervision, icometrix. GE Healthcare, Philips Healthcare, Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
